CRBU
Caribou Biosciences, Inc.Healthcare·Biotechnology
$2.36
$234M market cap
Revenue
$6.3M
Free Cash Flow
$-47.7M
Rev Growth
+0.0%
FCF Margin
-752.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of
2-Year Price History
$2.10+7.7%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 2.4 | -25.6 | -26.3 | -25.1 | -27.0 | -27.1 | -0.1 | 117.6 | 27.0 | 95.9 | -229.1% | -- | -- |
| Act | 2025-Q4 | 3.9 | -27.8 | -28.5 | -26.5 | -20.8 | -20.6 | -0.2 | 139.3 | 27.2 | 94.5 | -166.8% | -- | -- |
Valuation & Metrics
Market Stats
Price$2.36
Market Cap$234M
Enterprise Value$143M
P/S Ratio36.9x
P/FCF--
EV/FCF--
FCF Margin (TTM)-752.0%
FCF Yield-20.4%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$6.3M
Net Income$-51.6M
Free Cash Flow$-47.7M
Revenue Growth (YoY)+0.0%
EBITDA Margin-842.6%
Net Margin-813.7%
FCF Margin-752.0%
CapEx % of Revenue4.5%
SBC % of Revenue37.2%
ROIC-197.9%
WC Change % Rev-26.3%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares7.1M
Days to Cover4.4
Change (vs Prior)+5.2%
Need at least 2 settlement dates for chart
Employees
Headcount147
Revenue / Employee$43,116
Gross Profit / Employee$38,701
Cash Runway
29.6months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
26.9%(+11.6% YoY)
120 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
8.6%(+0.8% YoY)
9 filers
Vanguard, iShares, SPDR
Market makers
0.9%(+0.6% YoY)
5 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| PFIZER INC | $8.3M | $1.59 | +$0 | +$0 | +4.4% | $239M |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $7.2M | $1.90 | +$7.2M | +$7.2M | — | $4.04T |
| RENAISSANCE TECHNOLOGIES LLC | $4.9M | $1.84 | +$1.8M | +$4.9M | +1.2% | $63.91B |
| Kynam Capital Management, LP | $4.8M | $2.54 | +$0 | −$1.5M | +0.5% | $1.58B |
| BlackRock, Inc.Passive | $4.1M | $1.93 | +$4K | −$8.0M | -0.2% | $5.69T |
| TWO SIGMA INVESTMENTS, LP | $3.3M | $2.53 | +$1.4M | +$1.5M | -0.9% | $117.03B |
| BANK OF AMERICA CORP /DE/ | $2.5M | $3.48 | +$578K | +$374K | -0.1% | $1.36T |
| Aberdeen Group plc | $2.3M | $2.17 | −$335K | +$1.5M | -0.6% | $61.88B |
| MARSHALL WACE, LLP | $2.3M | $2.59 | +$617K | +$2.3M | +0.6% | $92.71B |
| MILLENNIUM MANAGEMENT LLC | $2.0M | $2.68 | +$584K | +$481K | -0.5% | $127.40B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $1.9M | $5.51 | +$78K | −$2.0M | +2.3% | $1.61T |
| Partner Fund Management, L.P. | $1.8M | $4.88 | +$0 | −$2.9M | -1.1% | $933M |
| MACKENZIE FINANCIAL CORP | $1.8M | $1.90 | +$1.8M | +$1.8M | -0.2% | $83.32B |
| ACADIAN ASSET MANAGEMENT LLC | $1.8M | $2.48 | +$1.6M | +$1.6M | -0.5% | $70.48B |
| SUSQUEHANNA INTERNATIONAL GROUP, LLPMM | $1.6M | $2.42 | −$369K | +$1.2M | -0.6% | $77.14B |
| FMR LLC | $1.4M | $1.85 | −$4K | −$1.4M | -0.0% | $1.89T |
| DIMENSIONAL FUND ADVISORS LPPassive | $1.3M | $4.61 | −$632K | −$1.4M | -0.4% | $480.92B |
| MAVERICK CAPITAL LTD | $1.2M | $5.43 | +$0 | +$0 | -1.4% | $8.60B |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1.1M | $5.93 | +$8K | −$318K | +0.7% | $645.81B |
| Cambridge Investment Research Advisors, Inc. | $1.0M | $0.91 | −$66K | −$124K | -0.4% | $38.49B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
+0.26%
avg per quarter
Holders (ex-self)
+0.27%
excl. this stock
Buyers (this Q)
-0.13%
42 buyers · $0.02B in
Sellers (this Q)
+0.78%
50 sellers · $0.01B out
alpha coverage: 88% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-6.8%
how holders react when this stock falls
On quiet Qs
-10.1%
−10% to +10% baseline
On rallies (+10%+)
+0.3%
how they react when this stock rises
Holders' portfolio flow this Q
+4.9%
inflows — adds are organic
Sellers' portfolio flow this Q
-4.4%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-4.9%
Holder mid (any stock)
-7.5%
Holder rally (any stock)
-7.1%
Biggest decreases this quarter
DekaBank Deutsche Girozentraleexited−$724KDIMENSIONAL FUND ADVISORS LP−$632Kα-0.4SUSQUEHANNA INTERNATIONAL GROUP, LLP−$369Kα-0.6Aberdeen Group plc−$335Kα-0.6GOLDMAN SACHS GROUP INC−$214Kα-0.2Siren, L.L.C.exited−$168KExodusPoint Capital Management, LPexited−$124KSquarepoint Ops LLCexited−$89KLighthouse Investment Partners, LLCexited−$70KCambridge Investment Research Advisors, Inc.−$66Kα-0.4
New buyers this quarter
Top-5 holders · 41.0%
PFIZER INC--
VANGUARD CAPITAL MANAGEMENT LLC--
RENAISSANCE TECHNOLOGIES LLC--
Kynam Capital Management, LP--
BlackRock, Inc.--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
Partner Fund Management, L.P.958KFMR LLC724KFARALLON CAPITAL MANAGEMENT LLC—Avidity Partners Management LP—PICTET ASSET MANAGEMENT SA—ALKEON CAPITAL MANAGEMENT LLC—JANUS HENDERSON GROUP PLC—Elmwood Wealth Management, Inc.—MAVERICK CAPITAL LTD653KRokos Capital Management LLP—
Analyst Coverage
Analyst Coverage
Price Targets
Last Year (1 analysts)$7.0019660.0%
Current Price$2.36
Analyst Ratings
9
Buy: 9Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$47K
5 txns · 4 insiders · 24,317 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-02-25 | SELL | Kelly Timothy P | officer: Chief Technology Officer | 6,228 | $1.93 | $12K | $141K |
| 2026-02-24 | SELL | Albertson Tina M. | officer: Chief Medical Officer | 1,066 | $1.96 | $2K | $134K |
| 2026-02-24 | SELL | Kelly Timothy P | officer: Chief Technology Officer | 3,147 | $1.96 | $6K | $156K |
| 2026-02-24 | SELL | Khan Ruhi Ahmad | officer: Chief Business Officer | 6,938 | $1.96 | $14K | $206K |
| 2026-02-24 | SELL | MCCLUNG BARBARA G | officer: Chief Legal Officer | 6,938 | $1.96 | $14K | $944K |
Order Flow (FINRA, ~3w lag)
38.3%retail+3.1pp
19.5%dark-1.8pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Caribou Biosciences: A CRISPR Pioneer Burning Cash at Warp Speed While Dismantling its Pipeline
Overall Risk
8/10
Fraud
4/10
Dilution
9/10
Insolvency
8/10
Earnings Overstated
5/10
Hidden Liabilities
3/10
Legal
7/10
Audit Warnings
6/10
Hidden Upside
4/10
Contextually Acceptable
5/10